Skip to main content
SpringerLink
Log in

Azilsartan: from bench to bedside

  • Review Article
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Renin-angiotensin-aldosterone system inhibitors are commonly used to control blood pressure (BP) because of their excellent efficacy and tolerability profiles. Oral azilsartan, an angiotensin receptor blocker (ARB), is indicated for the treatment of adults with essential hypertension. This article reviews the unique structure, pharmacology, therapeutic efficacy, and tolerability of azilsartan in this patient population. Azilsartan has shown higher affinity, a more potent inhibitory effect, and slower dissociation from angiotensin receptor II type I than other ARBs in in vitro studies. In several phase III randomized, double-blind, controlled clinical trials, oral azilsartan 40 or 80 mg once daily, as monotherapy or in combination therapy with chlorthalidone, hydrochlorothiazide, or amlodipine, provided superior BP control to control therapy. In head-to-head clinical studies, azilsartan at its highest therapeutic dose of 80 mg/day provided a BP reduction that was superior to that with olmesartan at its highest therapeutic dose of 40 mg/day. The safety and tolerability of azilsartan was similar to that of placebo and other ARBs. Apart from reducing BP, azilsartan also exhibited pleiotropic effects in in vitro studies. Future studies are needed to prove the role of azilsartan in cardiometabolic diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2224–60.

    Article  PubMed  PubMed Central  Google Scholar 

  2. World Health Organization. A global brief on hypertension: silent killer, global public health crisis. World Health Day 2013. Report, 1–39. Geneva: World Health Organization; 2013.

  3. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–357.

    Article  CAS  PubMed  Google Scholar 

  4. Pitt B, Segal R, Martinez FA, et al. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349(9054):747–52.

    Article  CAS  PubMed  Google Scholar 

  5. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–60.

    Article  CAS  PubMed  Google Scholar 

  6. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–9.

    Article  CAS  PubMed  Google Scholar 

  7. McMurray J, Solomon S, Pieper K, et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol. 2006;47(4):726–33.

    Article  CAS  PubMed  Google Scholar 

  8. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362(9703):759–66.

    Article  CAS  PubMed  Google Scholar 

  9. Jones JD, Jackson SH, Agboton C, et al. Azilsartan medoxomil (Edarbi): the eighth angiotensin II receptor blocker. P T. 2011;36(1):634–40.

    PubMed  PubMed Central  Google Scholar 

  10. Kohara Y, Imamiya E, Kubo K, et al. A new class of angiotensin II receptor antagonists with a novel acidic bioisostere. Bioorg Med Chem Lett. 1995;5(7):1903–8.

    Article  CAS  Google Scholar 

  11. Baker WL, White WB. Azilsartan medoxomil: new angiotensin II receptor antagonist for treatment of hypertension. Ann Pharmacother. 2011;45(12):1506–15.

    Article  CAS  PubMed  Google Scholar 

  12. Ojima M, Igata H, Tanaka M, et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther. 2011;336(3):801–8.

    Article  CAS  PubMed  Google Scholar 

  13. Edarbi label. Package insert: 2014 July 23 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/200796s006lbl.pdf. Accessed 11 Apr 2016.

  14. Preston RA, Karim A, Dudkowski C, et al. Single-center evaluation of the single-dose pharmacokinetics of the angiotensin II receptor antagonist azilsartan medoxomil in renal impairment. Clin Pharmacokinet. 2013;52(5):347–58.

    Article  CAS  PubMed  Google Scholar 

  15. White WB, Weber MA, Sica D, et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011;57(3):413–20.

    Article  CAS  PubMed  Google Scholar 

  16. Bakris GL, Weber MA, Sica D, et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich). 2011;13(2):81–8.

    Article  CAS  Google Scholar 

  17. Sica D, Weber MA, White WB, et al. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2011;13(7):467–72.

    Article  CAS  Google Scholar 

  18. Bonner G, Bakris GL, Sica D, et al. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. J Hum Hypertens. 2013;27(8):479–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Rakugi H, Enya K, Sugiura K, et al. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study. Hypertens Res. 2012;35(5):552–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Cushman WC, Bakris GL, White WB, et al. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. Hypertension. 2012;60(2):310–8.

    Article  CAS  PubMed  Google Scholar 

  21. Bakris GL, Sica D, White WB, et al. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Am J Med. 2012;125(12):1229.e1–1229.e10.

  22. Weber MA, White WB, Sica D, et al. Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension. Blood Press Monit. 2014;19(2):90–7.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Rakugi H, Nakata E, Sasaki E, et al. Evaluation of the efficacy and tolerability of fixed-dose combination therapy of azilsartan and amlodipine besylate in Japanese patients with grade I to II essential hypertension. Clin Ther. 2014;36(5):711–21.

    Article  CAS  PubMed  Google Scholar 

  24. Ukimura A, Matsuda H, Yamauchi Y, et al. Azilsartan is more effective as compared to olmesartan in hemodialysis patients with uncontrolled hypertension. J Nephrol Ther. 2015;5(1):193.

    Google Scholar 

  25. Kusuyama T, Ogata H, Takeshita H, et al. Effects of azilsartan compared to other angiotensin receptor blockers on left ventricular hypertrophy and the sympathetic nervous system in hemodialysis patients. Ther Apher Dial. 2014;18(5):398–403.

    Article  CAS  PubMed  Google Scholar 

  26. Zhao M, Li Y, Wang J, et al. Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky rats. Diabetes Obes Metab. 2011;13(12):1123–9.

    Article  CAS  PubMed  Google Scholar 

  27. Iwai M, Chen R, Imura Y, et al. TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation. Am J Hypertens. 2007;20(5):579–86.

    Article  CAS  PubMed  Google Scholar 

  28. Kusumoto K, Igata H, Ojima M, et al. Antihypertensive, insulin sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models. Eur J Pharmacol. 2011;669(1–3):84–93.

    Article  CAS  PubMed  Google Scholar 

  29. Kajiya T, Ho C, Wang J, et al. Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker. J Hypertens. 2011;29(12):2476–83.

    Article  CAS  PubMed  Google Scholar 

  30. Matsumoto S, Shimabukuro M, Fukuda D, et al. Azilsartan, an angiotensin II type 1 receptor blocker, restores endothelial function by reducing vascular inflammation and by increasing the phosphorylation ratio Ser1177/Thr497 of endothelial nitric oxide synthase in diabetic mice. Cardiovasc Diabetol. 2014;13:30.

    Article  PubMed  PubMed Central  Google Scholar 

  31. French CJ, Zaman AK, Sobel BE. The angiotensin receptor blocker, azilsartan medoxomil (TAK-491), suppresses vascular wall expression of plasminogen activator inhibitor type-I protein potentially facilitating the stabilization of atherosclerotic plaques. J Cardiovasc Pharmacol. 2011;58(2):143–8.

    Article  CAS  PubMed  Google Scholar 

  32. Nakamura Y, Suzuki S, Saitoh S, et al. New angiotensin II type 1 receptor blocker, azilsartan, attenuates cardiac remodeling after myocardial infarction. Biol Pharm Bull. 2013;36(8):1326–31.

    Article  CAS  PubMed  Google Scholar 

  33. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Affairs, Intas Pharmaceuticals Ltd., Ahmedabad, Gujarat, India

    Hiren Prajapati, Hanmant Barkate & Ramandeep Sharma

Authors
  1. Hiren Prajapati
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hanmant Barkate
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ramandeep Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiren Prajapati.

Ethics declarations

Conflict of interest

Hiren Prajapati, Hanmant Barkate and Ramandeep Sharma are salaried employees of Intas Pharmaceuticals Ltd., Ahmedabad, Gujarat, India.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Prajapati, H., Barkate, H. & Sharma, R. Azilsartan: from bench to bedside. Drugs Ther Perspect 32, 343–350 (2016). https://doi.org/10.1007/s40267-016-0308-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-016-0308-3

Keywords

Search

Navigation